This January, the article 'Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)' describing lead optimization process of a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations was published.

The result of this led JNJ-63576253 (also known as TRC-253) to a clinical stage as a next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC).

Drug candidate JNJ-63576253 contains 6-sulfanylidene-5,7-diazaspiro[3.4]octan-8-one moiety in its backbone.

We have made a set of compounds, which have such parts – the perfect start for your research!